Intracavernosal Invicorp as a second line injection therapy for erectile dysfunction after failure of alprostadil

Bazo, Alvaro; McAllister, Bría J.; Terry, Tim

doi:10.1111/ijun.12247

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Men being referred from primary care should have had a full trial of PDE5 inhibitors prior to referral, other patients come via diabetic or cardiac routes or following treatment for prostate cancer, including surgery, radiotherapy or hormone manipulation. 4,5 It is not uncommon for men to react with trepidation when offered the option of self-administered penile injection. The most common concern voiced during training sessions is that the injection will be painful, and men often worry that they will struggle to inject themselves in such a sensitive area.…”

Section: Introductionmentioning

confidence: 99%

“…Men will follow a standard pathway where they are assessed with IIEF/SHIM alongside a discussion of past medical and family history. Men being referred direct from primary care should have had a full trial of PDE5 inhibitors prior to referral, other patients come via diabetic or cardiac routes or following treatment for prostate cancer, including surgery, radiotherapy or hormone manipulation 4,5 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Patient's perspectives of injection‐site pain in intracavernosal therapy

McAllister

Bazo

2021

Int J of Uro Nursing

Self Cite

View full text Add to dashboard Cite

In this article, we report on patient's self-reported anticipated and actual experiences of injection-site pain while learning intracavernosal therapy. This is significant because anticipated pain has a strong bearing on the willingness of patients to pursue this form of treatment. We looked at 25 men undergoing teaching for intracavernosal injections for erectile dysfunction of mixed aetiology to assess their anticipated pain levels against actual pain levels experienced while injecting. Patients used a standard 0-10 pain score to indicate the level of pain they expected to experience while injecting prior to giving themselves an injection. They were subsequently asked to indicate how painful they actually found the injection. We found that, despite the fact that the majority of patients surveyed expected to experience moderate to severe levels of pain, post-injection they reported either no pain or mild pain. Men undergoing teaching for penile self-injection tend to overestimate the injection-site pain caused by such treatment. Being able to reassure prospective patients of the ease of injection therapy may improve uptake.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Patient's perspectives of injection‐site pain in intracavernosal therapy

McAllister

Bazo

2021

Int J of Uro Nursing

Self Cite

View full text Add to dashboard Cite

show abstract

An overview of the history, current strategies, and potential future treatment approaches in erectile dysfunction: a comprehensive review

Langarizadeh

Salary

Tavakoli

et al. 2023

Sexual Medicine Reviews

View full text Add to dashboard Cite

Introduction Erectile dysfunction (ED) is one of the most common urologic problems in men worldwide, with an approximately high incidence rate, significantly affecting patients’ quality of life and their sexual partners. Objectives Due to the association of this disorder with essential diseases such as cardiovascular disease and diabetes, its prevention and treatment are vital for overall human physiologic and psychological health. Along with reviewing the history of treatment and current methods, we seek new approaches to curb this issue in the future. Methods In this review, investigations were based on the focus of each section’s content or conducted on an ad hoc basis. Searches were performed in Scopus and PubMed. Results In recent years, many treatments for ED have been reported besides oral administration of phosphodiesterase 5 inhibitors such as sildenafil and tadalafil (approved by the Food and Drug Administration). Common oral medications, intracavernous injections, herbal therapies (eg, herbal phosphodiesterase 5 inhibitors), and topical/transdermal medications are routine ED treatment approaches. Moreover, some novel medications are innovative candidates for completing ED’s treatment protocols: stem cell injection, low-intensity extracorporeal shock wave therapy, platelet-rich plasma injection, gene therapy, amniotic fluid matrices, rho-kinase inhibitors, melanocortin receptor antagonists, maxi-K channel activators (ie, large-conductance calcium-activated potassium channels), guanylate cyclase activators, and nitric oxide donors. Conclusion Due to the importance of this complicated problem in men’s society, a faster course of treatment trends toward new methods is needed to increase efficiency. Combining the mentioned treatments and attentively examining their efficacy through programmed clinical trials can be a big step toward solving this global problem.

show abstract

Intracavernosal Invicorp as a second line injection therapy for erectile dysfunction after failure of alprostadil

Cited by 2 publications

References 6 publications

Patient's perspectives of injection‐site pain in intracavernosal therapy

Patient's perspectives of injection‐site pain in intracavernosal therapy

An overview of the history, current strategies, and potential future treatment approaches in erectile dysfunction: a comprehensive review

Contact Info

Product

Resources

About